Table 1.

Research Toward a Cure Trials of January 30, 2020. Source: Treatment action group, https://www.treatmentactiongroup.org/cure/trials/

Combination LRA and Immunotherapy Trials	Trial Registry Identifier(s)	Sponsor(s)	Phase	Estimated End Date
maraviroc, dolutegravir, dendritic cell vaccine, auranofin, nicotinamide	NCT02961829 (closed)	Federal University of São Paulo	Not listed	March 2020
ROADMAP: romidepsin + 3BNC117	NCT02850016 (closed to enrollment)	Rockefeller University	Phase IIa	December 2019
TITAN: lefitolimod + 3BNC117 + 10–1074 (TLR9 agonist + broadly neutralizing antibodies)	NCT03837756	University of Aarhus	Phase IIa	February 2021
eCLEAR: romidepsin + 3BNC117	NCT03041012	Aarhus University Hospital	Phase II	April 2021
Research In Viral Eradication of HIV Reservoirs (RIVER): ART, ChAdV63.HIVconsv & MVA.HIVconsv vaccines, vorinostat	NCT02336074 UK CPMS18010 (closed)	Imperial College London	Phase II	November 2022
iHIVARNA, MVA vector HIV vaccine, 10–1074, romidepsin, HIVACAR01 (personalized HIV RNA vaccine)	NCT03619278 (not yet open)	David Garcia Cinca	Phase I/IIa	July 2020
N-803 (recombinant human super agonist interleukin- 15 complex), VRC07–523LS, PGT121, haploidentical NK cells (haNK)	NCT04144335 (not yet open for enrollment)	University of Minnesota	Phase Ib	December 2020
Chidamide + CAR-T or TCR-T cell therapy	NCT03980691	Guangzhou 8th People’s Hospital	Phase I	December 2021
VRC07–523LS + vorinostat	NCT03803605	University of North Carolina, Chapel Hill	Phase I	July 2022
vorinostat + HXTC: HIV 1 antigen expanded specific T cell therapy	NCT03212989	University of North Carolina, Chapel Hill	Phase I	June 2021
Vorinostat +/− tamoxifen in postmenopausal women	NCT03382834 (closed)	NIAID	Phase I	June 2023
Vacc-4x + romidepsin	NCT02092116	Bionor Immuno AS/Celgene	Phase I/II	2019
AGS-004 + vorinostat	NCT02707900	University of North Carolina, Chapel Hill	Phase I	2019
MVA.HIVconsv + romidepsin	NCT02616874	IrsiCaixa	Phase I	2017